Loading patent…
AssigneesBrightGene Bio-Medical Technology Co., Ltd., Brightgene Pharmaceutical (Suzhou) Co. Ltd.
InventorsJiandong Yuan, Yunsong Song, Wenteng Zhen, Yue Cai, Jianing Gu, Yangqing Huang
Estimating the term…
A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.
A compound represented by any one of the following formulas I-3 or I-4 or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, isotopically labeled compound or prodrug thereof:
A GIP and GLP-1 dual receptor agonist, wherein, the GIP and GLP-1 dual receptor agonist is a compound represented by formula I-3 or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, isotopically labeled compound or prodrug thereof:
Dependencies are inferred from the claim text.